When sponsors use AI to draft clinical trial documents, regulatory scrutiny hinges on what the tool generates, not just that it generates. The FDA's January 2025 draft guidance introduced a seven-step credibility assessment for AI systems whose outputs inform regulatory decisions on safety, efficacy, or quality. Pure formatting and template tools fall outside this scope, but AI that generates eligibility criteria, dose logic, or safety summaries may not. The EMA's September 2024 reflection paper takes a broader stance, requiring risk management and transparency for any AI with high regulatory impact, regardless of FDA scope.
The practical stakes are measurable. Tufts research tracking 950 protocols found substantial amendment rates rising, with approval timelines stretching to 260 days, nearly triple the prior decade. Per-amendment costs range from $141,000 to over $535,000, excluding indirect delays. Many amendments stem from drafting errors: mismatched eligibility language, inconsistent consent forms, omitted requirements.
Domain-specific AI tools address this through structured architectures that enforce cross-document consistency at the data layer. A 2025 preprint on InformGen, an ICF-specific AI system, showed near-100% compliance across 18 FDA-derived rules, outperforming GPT-4o by 30 percentage points. The difference came from hard-coded regulatory constraints, not prompts. For electronic records, 21 CFR Part 11 audit trail requirements apply equally to AI-generated documents, with additional best practices for capturing model versions and inputs.